Adverse events related to COVID-19 vaccines: the need to strengthen pharmacovigilance monitoring systems

No Thumbnail Available
File version
Author(s)
Shrestha, Sunil
Khatri, Januka
Shakya, Sujyoti
Danekhu, Krisha
Khatiwada, Asmita Priyadarshini
Sah, Ranjit
Bhuvan, KC
Paudyal, Vibhu
Khanal, Saval
Rodriguez-Morales, Alfonso J
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
2021
Size
File type(s)
Location
License
Abstract

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by a new species of β-coronavirus genus named severe acute respiratory syndrome coronavirus 2. The COVID-19 pandemic, which started in late 2019 and continues as at mid-2021, has caused enormous damage to health and lives globally. The urgent public health need has led to the development of vaccines against COVID-19 in record-breaking time. The COVID-19 vaccines have been widely rolled out for the masses by many countries following approval for emergency use by the World Health Organization and regulatory agencies in many countries. In addition, several COVID-19 vaccine candidates are undergoing clinical trials. However, myths, fears, rumors, and misconceptions persist, particularly in regard to adverse events. In this commentary, we describe the adverse events associated with COVID-19 vaccines and discuss why it is essential to have a functional adverse event monitoring system in this context.

Journal Title

Drugs & Therapy Perspectives

Conference Title
Book Title
Edition
Volume

37

Issue

8

Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
Item Access Status
Note
Access the data
Related item(s)
Subject

Pharmacology and pharmaceutical sciences

Science & Technology

Life Sciences & Biomedicine

Pharmacology & Pharmacy

SAFETY

Persistent link to this record
Citation

Shrestha, S; Khatri, J; Shakya, S; Danekhu, K; Khatiwada, AP; Sah, R; Bhuvan, KC; Paudyal, V; Khanal, S; Rodriguez-Morales, AJ, Adverse events related to COVID-19 vaccines: the need to strengthen pharmacovigilance monitoring systems, Drugs & Therapy Perspectives, 2021, 37 (8), pp. 376-382

Collections